Giorgia Colombo

Giorgia Colombo

Auto-generated profile, based on publicly available information

Giorgia Colombo

Department of Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medical College, New York, NY 10021

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Pharmacological Research
Verified
Journal Article
Closed access
CTCristina Travelli
Cristina Travelli
GCGiorgia Colombo
Giorgia Colombo
SMSilvia Mola
Silvia Mola
AGArmando A. Genazzani
Armando A. Genazzani
Porta ChiaraPorta Chiara
Porta Chiara

27 April 2020 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
GCGiorgia Colombo
Giorgia Colombo
NCNausicaa Clemente
Nausicaa Clemente
AZAndrea Zito
Andrea Zito
CBCristiano Bracci
Cristiano Bracci
Federico Simone ColomboFederico Simone Colombo
Federico Simone Colombo
CTCristina Travelli
Cristina Travelli

9 March 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MSMarta Serafini
Marta Serafini
ETEnza Torre
Enza Torre
SASilvio Aprile
Silvio Aprile
EGerika del grosso
erika del grosso
AGAlessandro Gesù
Alessandro Gesù
SFSilvia Fallarini
Silvia Fallarini

1 March 2020 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
AGAmbra Grolla
Ambra Grolla
Riccardo MiggianoRiccardo Miggiano
Riccardo Miggiano
Daniele Di MarinoDaniele Di Marino
Daniele Di Marino
MBMichele M. Bianchi
Michele M. Bianchi
AGAlessandro Gori
Alessandro Gori
Silvia GaravagliaSilvia Garavaglia
Silvia Garavaglia
All cells require sustained intracellular energy flux, which is driven by redox chemistry at the subcellular level. NAD+, its phosphorylated variant NAD(P)+, and its reduced forms NAD(P)/NAD(P)H are all redox cofactors with key roles in energy metabolism and are substrates for several NAD-consuming enzymes (e.g. poly(ADP-ribose) polymerases, sirtuins, and others). The nicotinamide salvage pathway, constituted by nicotinamide mononucleotide adenylyltransferase (NMNAT) and nicotinamide phosphoribosyltransferase (NAMPT), mainly replenishes NAD+ in eukaryotes. However, unlike NMNAT1, NAMPT is not known to be a nuclear protein, prompting the question of how the nuclear NAD+ pool is maintained and how it is replenished upon NAD+ consumption. In the present work, using human and murine cells; immunoprecipitation, pulldown, and surface plasmon resonance assays; and immunofluorescence, small-angle X-ray scattering, and MS-based analyses, we report that GAPDH and NAMPT form a stable complex that is essential for nuclear translocation of NAMPT. This translocation furnishes NMN to replenish NAD+ to compensate for the activation of NAD-consuming enzymes by stressful stimuli induced by exposure to H2O2 or S-nitrosoglutathione and DNA damage inducers. These results indicate that by forming a complex with GAPDH, NAMPT can translocate to the nucleus and thereby sustain the stress-induced NMN/NAD+ salvage pathway.

25 October 2023 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
CTCristina Travelli
Cristina Travelli
GCGiorgia Colombo
Giorgia Colombo
MAMartina Aliotta
Martina Aliotta
FFFrancesca Fagiani
Francesca Fagiani
NFNatalia Fava
Natalia Fava
AGArmando A Genazzani
Armando A Genazzani
Background: Nicotinamide phosphoribosyltransferase (NAMPT) is a key intracellular enzyme that participates in nicotinamide adenine dinucleotide (NAD) homeostasis as well as a released cytokine (eNAMPT) that is elevated in inflammatory conditions and in cancer. In patients with breast cancer, circulating eNAMPT is elevated and its plasma levels correlate with prognosis and staging. In light of this, we investigated the contribution of eNAMPT in triple negative mammary carcinoma progression by investigating the effect of its neutralization via a specific neutralizing monoclonal antibody (C269). Methods: We used female BALB/c mice injected with 4T1 clone 5 cells and female C57BL6 injected with EO771 cells, evaluating tumoral size, spleen weight and number of metastases. We injected two times a week the anti-eNAMPT neutralizing antibody and we sacrificed the mice after 28 days. Harvested tumors were analyzed by histopathology, flow cytometry, western blot, immunohistochemistry, immunofluorescence and RNA sequencing to define tumor characteristics (isolating tumor infiltrating lymphocytes and tumoral cells) and to investigate the molecular mechanisms behind the observed phenotype. Moreover, we dissected the functional relationship between T cells and tumoral cells using three-dimensional (3D) co-cultures. Results: The neutralization of eNAMPT with C269 led to decreased tumor size and reduced number of lung metastases. RNA sequencing and functional assays showed that eNAMPT controlled T-cell response via the programmed death-ligand 1/programmed cell death protein 1 (PD-L1/PD-1) axis and its neutralization led to a restoration of antitumoral immune responses. In particular, eNAMPT neutralization was able to activate CD8+IFNγ+GrzB+ T cells, reducing the immunosuppressive phenotype of T regulatory cells. Conclusions: These studies indicate for the first time eNAMPT as a novel immunotherapeutic target for triple negative breast cancer.

1 November 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CTCristina Travelli
Cristina Travelli
SASilvio Aprile
Silvio Aprile
DMDaiana Mattoteia
Daiana Mattoteia
GCGiorgia Colombo
Giorgia Colombo
NCNausicaa Clemente
Nausicaa Clemente
UGUbaldina Galli
Ubaldina Galli